We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
When combined with an immune-boosting substance called an adjuvant, low doses of an experimental vaccine against a strain of avian influenza (H9N2) provoked a strong antibody response in human volunteers, according to scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
U.S. Ambassador to India David Mulford and the World Health Organization (WHO) have signed a joint agreement for tuberculosis (TB) control in India, Mulford announced.
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced that it has entered into an exclusive license agreement with a Japanese pharmaceutical company, Seikagaku Corporation, to develop and market CF101 in Japan for the treatment of inflammatory indications including rheumatoid arthritis (RA) but not including ophthalmic indications.
PDI, Inc. a contract sales and marketing services provider to the biopharmaceutical industry, today announced that it has received verbal notification from GlaxoSmithKline (GSK) of its intention not to renew its contract sales engagement with PDI for 2007.
Moving from egg-based production of vaccines to the use of cell-culture technologies in existing manufacturing plants is cheaper and quicker than building new facilities to handle a flu pandemic within the next five years, new research suggests.
Dutch biotechnology company Crucell N.V. announced today that Quinvaxem, its fully liquid pentavalent vaccine co-developed with Novartis Vaccines and Diagnostics, has been granted 'prequalification' by the World Health Organization (WHO).
The U.S. Agency for International Development (USAID) has announced a $100 million award to the nonprofit research organization RTI International to reduce the impact of tropical diseases in developing nations, including those in Africa.